Altered vancomycin pharmacokinetics in obese and morbidly obese patients: What we have learned over the past 30 years

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1305-1310

  Grace, Edward ^a  

^a PRESBYTERIAN COLLEGE   (United States)

Author keywords

Antibiotics; Glycopeptides; Overweight; Volume of distribution

Indexed keywords

ALBUMIN; CHOLESTEROL; OROSOMUCOID; TRIACYLGLYCEROL; VANCOMYCIN;

ADIPOSE TISSUE; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD FLOW; BLOOD VOLUME; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; GENDER; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HUMAN; HYDROPHILICITY; HYDROSTATIC PRESSURE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY MASS; LEAN BODY WEIGHT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBID OBESITY; MUSCLE MASS; NONHUMAN; OBESITY; PROTEIN BINDING; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-BACTERIAL AGENTS; HUMANS; OBESITY; SERUM; VANCOMYCIN;

EID: 84861180225     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks066     Document Type: Article

References (46)

1. Krogstad DJ, Moellering RC, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980; 20: 197-201.
2. Matzke GR, McGory RW, Halstenson CE et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 4: 433-7.
3. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848-52.
4. Ambrose PJ, Winter ME. Vancomycin. In: Winter ME, ed. Basic Clinical Pharmacokinetics, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2004; 451-76.
5. Bauer LA. Applied Clinical Pharmacokinetics. New York: McGraw Hill, Medical Publishing Division, 2001; 180-261.
6. WHO. Obesity and Overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (28 November 2011, date last accessed).
7. Kelly T, Yang W, Chen CS et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32: 1431-7.
8. CDC. U.S. Obesity Trends. http://www.cdc.gov/obesity/data/trends.html (9 November 2011, date last accessed).
9. Pikhart H, Bobak M, Malyutina S et al. Obesity and education in three countries of the Central and Eastern Europe: the HAPIEE study. Cent Eur J Public Health 2007; 15: 140-2.
10. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-8.
11. Bearden DT, Rodvold KA. Dosage adjustments for antimicrobials in obese patients. Clin Pharmacokinet 2000; 28: 415-26.
12. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients: insights of the Society of Infectious Disease Pharmacists. Pharmacotherapy 2007; 27: 1081-91.
13. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66: 642-8.
14. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean body weight. Clin Pharmacokinet 2005; 44: 1051-65.
15. Duffull SB, Dooley MJ, Green B et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43: 1167-78.
16. Hanley MJ, Abernethy DR, Greenblatt DJ. Effects of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
17. WHO. BMI Classification. http://apps.who.int/bmi/index.jsp?intopage=intro_3.html (9 November 2011, date last accessed).
18. Blouin RA, Chandler MH. Special pharmacokinetic considerations in the obese. In: Evan WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics; Principles of Therapeutic Drug Monitoring, 3rd edn. Spokane, Washington: Applied Therapeutics, 1992.
19. Craig WA. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
20. Morita K, Yamaji A. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha-1-acid glycoprotein levels. Ther Drug Monit 1995; 17: 107-12.
21. Vadiei K, Lopez-Berestein G, Luke DR. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obes 1990; 14: 465-72.
22. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 3rd edn. Baltimore: Williams & Wilkins, 1991.
23. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm 1987; 6: 706-14.
24. Marvrelis PG, Ammon HV, Gleysteen JJ et al. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology 1983; 3: 226-31.
25. Wasan KM, Lopez-Berestein G. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res 1993; 24: 395-401.
26. Stokholm KH, Brochner-Mortenson J, Holland-Carlsen PF. Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes 1980; 4: 57-63.
27. Alexander JK, Dennis EW, Smith WG et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962-1963; 1: 39-44.
28. Naeye R, Roode P. The size and numbers of cells in visceral organs in human obesity. Am J Clin Pathol 1970; 54: 251-3.
29. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-22.
30. Eknoyan G. Obesity, diabetes and chronic kidney disease. Curr Diab Rep 2007; 7: 449-53.
31. Henegar JR, Bigler SA, Tyagi SC et al. Functional and structural changes in kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-7.
32. Blouin RA, Bauer LA, Miller DD et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
33. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram. Ann Intern Med 1981; 94: 343-6.
34. Vance-Bryan K, Guay DR, Gilliand SS et al. Effects of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
35. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effects of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8.
36. Thomson AH, Staaz CE, Tobin CM et al. Development and evaluation of a vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63: 1050-7.
37. Ackerman BH, Taylor EH, Olsen KM et al. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm 1988; 22: 300-3.
38. Butterfield JM, Patel N, Pai MP et al. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011; 55: 4277-82.
39. Bauer LA, Black DJ. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-5.
40. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988; 84: 1053-60.
41. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
42. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006; 63: 2365-70.
43. Birt JK, Chandler MH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit 1990; 12: 206-9.
44. Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP 1989; 23: 294-300.
45. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-aged and elderly men. Am J Hosp Pharm 1994; 51: 798-800.
46. Winter ME. Vancomycin. In: Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics, 2nd edn. Vancouver, WA: Applied Therapeutics, 1988; 357-71.